Blueprint Medicines (STU:2L9) FCF Yield % : -3.85 (As of Apr. 09, 2025)

View and export this data going back to 2017. Start your Free Trial

What is Blueprint Medicines FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Blueprint Medicines's Trailing 12-Month Free Cash Flow is €-182.7 Mil, and Market Cap is €4,647.9 Mil. Therefore, Blueprint Medicines's FCF Yield % for today is -3.85%.

The historical rank and industry rank for Blueprint Medicines's FCF Yield % or its related term are showing as below:

STU:2L9' s FCF Yield % Range Over the Past 10 Years
Min: -26.36 Med: -5.79 Max: 8.4
Current: -3.85

During the past 12 years, the highest FCF Yield % of Blueprint Medicines was 8.40%. The lowest was -26.36%. And the median was -5.79%.

STU:2L9's FCF Yield % is ranked better than
72.52% of 1499 companies
in the Biotechnology industry
Industry Median: -16.56 vs STU:2L9: -3.85

Blueprint Medicines's FCF Margin % for the quarter that ended in Dec. 2024 was -20.70%.

Blueprint Medicines FCF Yield % Historical Data

The historical data trend for Blueprint Medicines's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines FCF Yield % Chart

Blueprint Medicines Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Yield %

Get a 7-Day Free Trial

5.78

-8.77

-20.28

-8.33

-3.50

Blueprint Medicines Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Yield %	Get a 7-Day Free Trial															-6.15	-6.82	-2.96	-0.95	-2.15

Competitive Comparison of Blueprint Medicines's FCF Yield %

For the Biotechnology subindustry, Blueprint Medicines's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Blueprint Medicines's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's FCF Yield % falls into.

Save Embed

;

Save Embed

;

Blueprint Medicines FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Blueprint Medicines's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-188.342	/	5388.76096
	=	-3.50%

Blueprint Medicines's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-28.933	*	4	/	5388.76096
	=	-2.15%

Blueprint Medicines FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Blueprint Medicines FCF Yield % Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Blueprint Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (STU:2L9) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

BPMC:USA 0HOJ:UK 2L9:Germany

Address

45 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Blueprint Medicines Headlines

No Headlines